Heart failure & cardiomyopathies
Representativeness of the PIONEER-HF and PARAGLIDE-HF in Patients Hospitalized with Acute Heart Failure
Authors' conclusion
Using trial criteria, only 31.3% of AHF patients were eligible for sacubitril-valsartan. Yet, non-eligible patients demonstrated similar outcomes to eligible patients
Study context
- Population
- Patients hospitalised with AHF, Chang Gung Research Database, August 2008 to August 2017
- Participants
- 28,293 patients
- Exposure
- Trial-non-eligible vs trial-eligible real-world AHF patients
- PIONEER-HF eligiblen = 3,683reference
- PIONEER-HF non-eligiblen = 3,502
- PARAGLIDE-HF eligiblen = 5,191reference
- PARAGLIDE-HF non-eligiblen = 5,832
- Outcome
- HF hospitalisation and cardiovascular (CV) death
- Follow-up
- Mean 3.5 years
Main finding
As reported in the abstract
PIONEER-HF non-eligible vs PIONEER-HF eligible
Estimate (95% CI)
Adjusted hazard ratio
0.95(0.88–1.04)
PARAGLIDE-HF non-eligible vs PARAGLIDE-HF eligible
Estimate (95% CI)
Adjusted hazard ratio
0.97(0.90–1.04)
Observational data: associations, not effects.
Further findings
Eligibility for sacubitril-valsartan by trial criteria
- AHF patients eligible
- 31.3%
Original publication
Representativeness of the PIONEER-HF and PARAGLIDE-HF in Patients Hospitalized with Acute Heart Failure. ESC Heart Fail. Published 18 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →